Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic and the Therapeutic Potential of HS-20105 for Injection in Patients With Advanced Solid Tumors.
Latest Information Update: 27 Nov 2023
At a glance
- Drugs HS 20105 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 27 Nov 2023 New trial record